Lisata Therapeutics, Inc. (LSTA) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-2.62 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.40 vs est $-2.62 (beat +8.3%). 2025: actual $-1.91 vs est $-2.33 (beat +17.8%). Analyst accuracy: 85%.
LSTA Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Lisata Therapeutics, Inc. in the past 3 months
EPS Estimates — LSTA
85%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.40
vs Est –$2.62
▲ 9.0% off
2025
Actual –$1.91
vs Est –$2.33
▲ 21.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — LSTA
56%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 7.0% off
2025
Actual $0.000B
vs Est $0.000B
▲ 80.4% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
